JUNSHI BIOSCIENCES ANNOUNCES ACCEPTANCE OF THE SUPPLEMENTAL APPLICATION FOR TORIPALIMAB PLUS CHEMOTHERAPY AS PERIOPERATIVE TREATMENT FOR RESECTABLE STAGE Ⅱ-Ⅲ NSCLC

Reuters · 2d ago

Please log in to view news